Portola Pharmaceuticals (Nasdaq: PTLA), announced that it has licensed lead development and commercial rights to its investigational agent andexanet alfa ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

BMO Capital Reiterates Outperform on Pfizer (PFE) Following 4Q February 3, 2016 8:21 AM Portola Pharmaceuticals Enters Into Licensing Agreements for Investigational Agent Andexanet Alfa in Japan Worth Up to $120 MillionFebruary 1, 2016 6:55 AM Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in JapanFebruary 1, 2016 6:55 AM Form 4 PORTOLA PHARMACEUTICALS For: Jan 27 Filed by: Lis WilliamJanuary 29, 2016 5:15 PM